Support for Seasonal and Year-Round Allergic Symptoms

This medication helps address symptom clusters associated with allergic rhinitis (e.g., hay fever or allergy to dust mites and pet dander), which often includes symptoms like sneezing, a runny or itchy nose, and watery eyes. Used across domains where additional symptomatic support is needed, for example, it provides support that helps ease the overall symptom burden, contributing to easing the overall symptom load during symptomatic periods. The medicine is applied across domains where short-term symptom management is appropriate.

Support for Hives and Skin Reaction Discomfort (Urticaria)

Desloratadine Actavis is commonly used across conditions presenting with episodic or fluctuating manifestations, specifically for allergic rhinitis and urticaria (hives). It may assist with symptoms related to inflammatory or irritative states.

“This medicine is commonly used for short-term symptomatic assistance relevant in situations requiring additional management of discomfort due to allergic reactions.”

This support helps patients cope more steadily with symptom fluctuations. Relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden, it helps address symptoms that may appear suddenly or fluctuate.

Quick Fact: Support for Symptoms of Itching and Hives

Regulatory References

1. European Medicines Agency overview

Who Can and Cannot Use Desloratadine Actavis?

The population eligibility for Desloratadine Actavis is strictly defined by regulatory documents based on age, physiological status, and underlying medical conditions.

Contraindicated Populations

Use of Desloratadine Actavis is absolutely contraindicated if a patient has a known hypersensitivity to the active substance desloratadine, the parent compound loratadine, or any of the inactive ingredients listed in the formulation.

Age-Specific Eligibility

The medicine is approved for adults and adolescents aged 12 years and older. Pediatric use is restricted and formulation-specific: the 5 mg film-coated tablet is not recommended for children under 12 years of age. Use in infants under 6 months old is not established and therefore contraindicated.

Conditional Use and Restrictions

Certain populations require caution and conditional use due to regulatory warnings:

• Pregnancy and Lactation: Use during pregnancy and by breastfeeding mothers is not recommended, as desloratadine is excreted into breast milk.
• Organ Impairment: Caution is advised for patients with severe renal impairment or hepatic impairment due to the potential for altered drug exposure.
• Comorbidities: Caution is required for patients with predisposing factors for seizures.

Interactions with other medicines and products

The official interaction profile for single-component desloratadine is structured around pharmacokinetic findings and co-substance considerations. No medicinal products are formally listed as contraindicated combinations in regulatory documents.

A pharmacokinetic interaction is documented when desloratadine is co-administered with specific agents, including the antifungal ketoconazole, macrolide antibiotics like erythromycin and azithromycin, the H2-receptor antagonist cimetidine, and the antidepressant fluoxetine. Co-administration with these agents is officially stated to increase the systemic exposure (plasma concentrations or AUC) of desloratadine and its metabolite. However, clinical trials did not show this rise in exposure resulted in clinically relevant changes in the medicine’s safety profile.

Regarding other substances, co-use with alcohol has been associated with post-marketing reports of alcohol intolerance and intoxication, although clinical studies did not demonstrate potentiation of impairment. The official documentation confirms that neither food nor grapefruit juice affects the bioavailability of desloratadine, meaning it can be administered regardless of meals. No mandatory timing or separation requirements are specified for interacting agents.

Furthermore, population-specific notes indicate that exposure is significantly increased in patients with hepatic impairment and severe renal impairment due to altered clearance.

Primary Receptor Interaction

Desloratadine is a non-sedating, long-acting compound that functions as a mathbfperipheral H1-receptor antagonist. It is the active metabolite of loratadine. The compound interacts with the histamine H1-receptor, resulting in the stabilization of the receptor in an inactive conformation.

Modulation of Inflammatory Mediators

Following oral administration, desloratadine mathbfinhibits histamine release from mast cells and basophils. This inhibition is associated with the suppression of downstream inflammatory mediators, including select chemokines and cytokines. Desloratadine also mathbfinterferes with the adhesion of mathbfP-selectin to endothelial cells. Furthermore, it inhibits the release of proinflammatory mediators such as leukotriene C4 (LTC4) and prostaglandin D2 (PGD2).

How to Use Desloratadine Actavis

Desloratadine Actavis is intended for oral use and is administered as a single dose once daily, regardless of whether the patient has consumed food. The medicine is available in several forms, including a 5 mg film-coated tablet, a 0.5 mg/mL oral solution, and oral disintegrating tablets (ODT) in 2.5 mg and 5 mg strengths.

Official Dosing and Frequency

Special Administration Requirements

For adults with known hepatic or renal impairment, the official label recommends an initial starting dose of 5 mg every other day based on pharmacokinetic considerations. No adjustment is generally recommended for older subjects.

Specific administration techniques apply to the different forms. The film-coated tablet must be swallowed whole with water. In contrast, the oral disintegrating tablet should be placed on the tongue to dissolve and does not require water for administration. When using the oral solution, doses must be precisely measured using a calibrated measuring dropper or syringe to ensure accuracy. If a dose is missed, it should be taken as soon as remembered, but subsequent doses should be maintained at the regular schedule; doses should not be doubled.

Recent Clinical Evidence Overview

Desloratadine is a non-sedating, long-acting antihistamine used to manage symptoms associated with allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives).

Research has explored the compound's mechanism of action, which involves its function as a selective antagonist of the peripheral histamine H1 receptor. This action blocks histamine from binding to these receptors, thereby preventing the cascade of symptoms typically associated with allergic reactions.

Efficacy and Study Findings

Clinical trials, including randomized, double-blind, placebo-controlled studies, have evaluated the efficacy and tolerability of desloratadine. Key findings focus on its use in the two primary indicated conditions:

• Allergic Rhinitis (AR): Studies have demonstrated that desloratadine use is associated with a reduction in key nasal symptoms (such as sneezing, itching, and congestion) and ocular symptoms (like tearing and redness). Symptom relief has been reported to occur rapidly and is generally maintained over the treatment period.

• Chronic Urticaria (CIU): Research indicates that the compound is associated with a significant reduction in CIU symptoms, including the severity of pruritus (itching), the number of hives, and the size of the largest wheal. Improvements in quality of life metrics, such as reduced sleep disturbance, have also been reported in affected individuals.

Safety and Tolerability

Desloratadine has been extensively studied for its safety profile. Unlike older antihistamines, it is classified as non-sedating due to its limited ability to cross the blood-brain barrier. The reported adverse event profile from clinical trials is generally comparable to that of a placebo. Common adverse events observed across studies include fatigue, dry mouth, and headache.

Common questions about Desloratadine Actavis (FAQ)

Q: What is Desloratadine Actavis used for?

Desloratadine Actavis is an antihistamine medication indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria (hives).

Q: When is the best time of day to take this medication?

The prescribing information generally indicates that Desloratadine Actavis can be taken once a day, with or without food. Patients should follow the specific timing instructions provided by their healthcare professional.

Q: Can I drink alcohol while taking Desloratadine Actavis?

Clinical studies have not shown that Desloratadine Actavis increases the effects of alcohol. However, it is generally recommended that patients use caution and consult a healthcare provider regarding alcohol consumption while taking any medication.

Q: What are the most common side effects?

The most frequently reported side effects in clinical trials included headache, dry mouth, and fatigue. Not all patients experience side effects, and if a patient has any concerns about adverse reactions, they should speak with a healthcare professional.

How to Store and Dispose of Desloratadine Actavis

The storage and disposal of Desloratadine Actavis must comply with the conditions specified in official regulatory labeling to ensure product quality and environmental safety.

Storage Requirements

Disposal Instructions

Disposal of unused or expired Desloratadine Actavis is strictly regulated. The medicine must not be disposed of via wastewater or household waste. All unused medicinal product or waste material must be taken back to a pharmacy or disposal facility and carried out according to local requirements.